Novartis | NVS - DEBITO





DEBITO Cambiamento Data
AbbVie USD 67.5B 67.5B 2025-12
Amgen USD 54.6B 17M 2025-12
AstraZeneca USD 33.92B 4.3B 2026-03
Bausch Health Companies USD 20.85B 191M 2025-12
Biogen USD 6.56B 275.1M 2026-03
Bristol-Myers Squibb USD 47.14B 3.9B 2025-12
Canopy Growth CAD 259.33M 68.47M 2025-09
Corcept Therapeutics USD 6.11M 251K 2025-12
Drreddys Laboratories INR 67.73B 19.09B 2025-12
Eli Lilly USD 42.5B 3.6M 2025-12
Gilead Sciences USD 24.94B 5M 2025-12
GlaxoSmithKline GBP 19.06B 1.34B 2026-03
Glaxosmithkline GBP 17.75B 396M 2025-09
J&J USD 47.93B 2.14B 2025-12
Merck USD 49.34B 7.97B 2025-12
Novartis USD 47B 11.62B 2026-03
Novartis USD 32.02B 615M 2025-09
Pacira USD 367.66M 4.53M 2026-03
Perrigo USD 3.64B 4.5M 2025-12
Pfizer USD 63.73B 231M 2026-03
Phibro Animal Health USD 474.17M 730K 2024-09
Prestige Brands USD 1.08B 38.27M 2025-12
Roche Holding CHF 33.03B 1.41B 2025-06
Sanofi EUR 20.33B 1.43B 2025-12
Sanofi EUR 21.76B 530M 2025-09
Supernus Pharmaceuticals USD 40.98M 1.23M 2025-12
Zoetis USD 9.24B 1.96B 2025-12